Paper36936577
Endometrial cancer: molecular classification and future treatments.
Corr B and 3 others. BMJ Med, 2022. Cited by 76 papers, by iCite.
Cite this record
ConductScience Library. Endometrial cancer: molecular classification and future treatments. Papers, record 36936577. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36936577
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References87
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33375706 | HER2 Status in High-Risk Endometrial Cancers (PORTEC-3): Relationship with Histotype, Molecular Classification, and Clinical Outcomes. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/33375706 | PubMed |
| 2 | 10841828 | Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. | J Natl Cancer Inst | 2000 | https://conductscience.org/library/papers/10841828 | PubMed |
| 3 | 35045221 | Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer. | N Engl J Med | 2022 | https://conductscience.org/library/papers/35045221 | PubMed |
| 4 | 27159395 | Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer. | J Clin Invest | 2016 | https://conductscience.org/library/papers/27159395 | PubMed |
| 5 | 25878334 | POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer. | Clin Cancer Res | 2015 | https://conductscience.org/library/papers/25878334 | PubMed |
| 6 | 23550210 | Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. | Sci Signal | 2013 | https://conductscience.org/library/papers/23550210 | PubMed |
| 7 | 30415991 | Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression. | Gynecol Oncol | 2019 | https://conductscience.org/library/papers/30415991 | PubMed |
| 8 | 21903247 | The role of the phosphatidylinositol 3-kinase (PI3K) pathway in the development and treatment of uterine cancer. | Gynecol Oncol | 2011 | https://conductscience.org/library/papers/21903247 | PubMed |
| 9 | 31086306 | The proportion of endometrial cancers associated with Lynch syndrome: a systematic review of the literature and meta-analysis. | Genet Med | 2019 | https://conductscience.org/library/papers/31086306 | PubMed |
| 10 | 20681032 | A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. | Cancer | 2010 | https://conductscience.org/library/papers/20681032 | PubMed |
| 11 | 33046573 | PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer. | Int J Gynecol Cancer | 2020 | https://conductscience.org/library/papers/33046573 | PubMed |
| 12 | 28061006 | Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer. | Cancer | 2017 | https://conductscience.org/library/papers/28061006 | PubMed |
| 13 | 19840887 | Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. | Gynecol Oncol | 2010 | https://conductscience.org/library/papers/19840887 | PubMed |
| 14 | 35658479 | TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study. | J Clin Oncol | 2022 | https://conductscience.org/library/papers/35658479 | PubMed |
| 15 | 34269576 | Discovery of Pemigatinib: A Potent and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor. | J Med Chem | 2021 | https://conductscience.org/library/papers/34269576 | PubMed |
| 16 | 33541735 | Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study. | Gynecol Oncol | 2021 | https://conductscience.org/library/papers/33541735 | PubMed |
| 17 | 3652025 | Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. | Cancer | 1987 | https://conductscience.org/library/papers/3652025 | PubMed |
| 18 | 26028255 | PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. | N Engl J Med | 2015 | https://conductscience.org/library/papers/26028255 | PubMed |
| 19 | 31829447 | Clinicopathological and molecular characterisation of 'multiple-classifier' endometrial carcinomas. | J Pathol | 2020 | https://conductscience.org/library/papers/31829447 | PubMed |
| 20 | 31415061 | Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types. | JAMA Oncol | 2019 | https://conductscience.org/library/papers/31415061 | PubMed |
Cited by58
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 76 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42793688 | Molecular Classification of Endometrial Cancer in the Era of Precision Oncology: Prognostic Significance, Emerging Biomarkers, and Personalized Therapeutic Strategies-A Systematic Review. | Diagnostics (Basel) | 2026 | https://conductscience.org/library/papers/42793688 | PubMed |
| 42621259 | Envafolimab - novel anti-PD-1/PD-L1 antibody in cancer treatment. | Front Immunol | 2026 | https://conductscience.org/library/papers/42621259 | PubMed |
| 42598125 | Current status and targeted therapies in endometrial cancer: Molecular classification-driven treatment strategies (Review). | Oncol Lett | 2026 | https://conductscience.org/library/papers/42598125 | PubMed |
| 42494604 | Molecular classification and immunotherapy in fertility-sparing treatment for endometrial cancer: opportunities and challenges. | Front Oncol | 2026 | https://conductscience.org/library/papers/42494604 | PubMed |
| 42333330 | Endometrial Serous Carcinoma Arising From Adenomyosis. | Cureus | 2026 | https://conductscience.org/library/papers/42333330 | PubMed |
| 42325921 | Comprehensive bioinformatics analysis of NCAPH expression and its clinical importance in endometrial cancer. | Oncol Lett | 2026 | https://conductscience.org/library/papers/42325921 | PubMed |
| 41806063 | Exploring the role of IGHV3-30 in the immune microenvironment and prognosis of uterine endometrial cancer. | Discov Oncol | 2026 | https://conductscience.org/library/papers/41806063 | PubMed |
| 41681828 | The Influence of Molecular Factors on the Effectiveness of New Therapies in Endometrial Cancer-Latest Evidence and Clinical Trials. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/41681828 | PubMed |
| 41595105 | Molecular Classification and Clinical Outcomes in Endometrial Cancer: Real-World Evidence from a Tertiary Care Center. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/41595105 | PubMed |
| 41516364 | Special Issue "Molecular Advances in Obstetrical and Gynaecological Disorders". | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/41516364 | PubMed |
| 41514564 | Molecular Classification of Endometrial Carcinomas: Review and Recent Updates. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/41514564 | PubMed |
| 41383623 | Inflammation-driven mechanisms in endometrial cancer: pathways from inflammatory microenvironment remodeling to immune escape. | Front Immunol | 2025 | https://conductscience.org/library/papers/41383623 | PubMed |
| 41378048 | SAMD4B: a novel prognostic biomarker of endometrial carcinoma. | Transl Cancer Res | 2025 | https://conductscience.org/library/papers/41378048 | PubMed |
| 41315187 | Dissecting endometrial cancer complexity in response to standard and targeted therapies. | Cell Death Dis | 2025 | https://conductscience.org/library/papers/41315187 | PubMed |
| 41300972 | Association Between MMR Status and Prognostic Pathological Factors in Endometrioid Endometrial Cancer-A Single-Center Retrospective Study. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/41300972 | PubMed |
| 41226033 | Comparison of Long Non-Coding RNA Expressions in Endometrial Polyp and Endometrial Cancer Cases. | Diagnostics (Basel) | 2025 | https://conductscience.org/library/papers/41226033 | PubMed |
| 41211166 | Bispecific antibodies in the treatment of epithelial ovarian, endometrial, and cervical cancer: an overview of current applications, challenges, and emerging opportunities. | Explor Target Antitumor Ther | 2025 | https://conductscience.org/library/papers/41211166 | PubMed |
| 41003831 | LncRNA DEPDC1-AS1 drives the progression of endometrial carcinoma by regulating miR-508-3p. | Discov Oncol | 2025 | https://conductscience.org/library/papers/41003831 | PubMed |
| 40968748 | Enhancement of circular RNA 0002577 in serum exosomes in patients with endometrial cancer accelerates disease progression via general transcription factor II-I repeat domain-containing 1 (GTF2IRD1). | J Gynecol Oncol | 2026 | https://conductscience.org/library/papers/40968748 | PubMed |
| 40940815 | Integrating Multi-Omics in Endometrial Cancer: From Molecular Insights to Clinical Applications. | Cells | 2025 | https://conductscience.org/library/papers/40940815 | PubMed |
Genes40
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36936577
GET https://conductscience.org/api/papers/v1/36936577/references?page=2